VACCINEX, Inc. (VCNX) intrinsic value & 10-year financials
VACCINEX, Inc. (VCNX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 9 fiscal years revenue grew 31.2% a year to $601.0K, with an average return on invested capital of 518.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.00
- Market cap
- $2.1M
- Revenue (FY2024)
- $601.0K
- Revenue growth (9-yr CAGR)
- 31.2%
- ROIC (10-yr avg)
- 518.9%
- Free cash flow (FY2024)
- -$16.2M
VCNX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | $601.0K | -$18.6M | -$8.88 | -$16.2M | -3117.3% | 512.2% |
| FY2023 | $570.0K | -$20.3M | -$43.68 | -$17.3M | -4014.9% | 990.3% |
| FY2022 | $275.0K | -$19.8M | -$0.47 | -$19.2M | -7238.5% | 2205.7% |
| FY2021 | $900.0K | -$22.4M | -$0.78 | -$25.3M | -2498.9% | 121.7% |
| FY2020 | $50.0K | -$28.9M | — | -$28.9M | -56662.0% | 78.6% |
| FY2019 | $523.0K | -$31.9M | — | -$30.8M | -6121.4% | 183.7% |
| FY2018 | $724.0K | -$29.5M | — | -$25.5M | -3768.1% | 40.7% |
| FY2017 | $90.0K | -$18.7M | — | -$21.5M | -23448.9% | 18.2% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
VACCINEX, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
VACCINEX, INC. has earned high returns on invested capital, averaging 37.3% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
VACCINEX, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, VACCINEX, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-294.96 per share.